+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Retinitis Pigmentosa (RP) - Epidemiology Forecast to 2030

  • ID: 5010950
  • Report
  • April 2020
  • Region: Global
  • 118 pages
  • DelveInsight
Overview

‘Retinitis Pigmentosa (RP) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Retinitis Pigmentosa (RP) epidemiology in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

Retinitis Pigmentosa (RP)
Retinitis Pigmentosa (RP) refers to a group of inherited retinal disorders causing retinal degeneration and blindness. RP is characterized by progressive bilateral degeneration of the rod and cone photoreceptors that leads to night blindness and progressive visual field defects. Individuals with RP lose their vision because of the gradual degeneration of photoreceptor (light-sensing) cells of the retina. In most forms of RP (rod-cone dystrophy), night blindness is one of the earliest and most frequent symptoms. On the basis of clinical impact, RP is classified into three categories that include, non-syndromic, or "simple" (not affecting other organs or tissues), Syndromic (affecting other neurosensory systems such as hearing), and Systemic (affecting multiple tissues. Non-syndromic RP has three-stage: early stage, mid and end-stage. Non-syndromic RP is further subcategorized as autosomal dominant RP, autosomal recessive RP, X-linked RP, sporadic/simplex RP, and Leber congenital amaurosis (LCA).

Syndromic and Systemic RP are subcategorized into usher syndrome, bardet-biedl syndrome, and others.

Retinitis Pigmentosa (RP) Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent Cases of Retinitis Pigmentosa in the 7MM, Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM, Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM, Subtype-Specific Diagnosed Prevalence of Syndromic and Systemic RP in the 7MM, and Subtype-specific Diagnosed Prevalent Cases of Non-Syndromic RP in the 7MM) scenario of Retinitis Pigmentosa in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017-2030.

Retinitis Pigmentosa (RP) Detailed Epidemiology Segmentation

According to the publisher's, the total diagnosed prevalent population of Retinitis Pigmentosa (RP) in the 7MM is 253,420 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

The estimates show the highest diagnosed prevalence of RP in the United States with 108,787 cases in 2017.

Among the European 5 countries, Germany had the highest diagnosed prevalent population of RP with 30,642 cases, followed by France and the United Kingdom. On the other hand, Spain had the lowest diagnosed prevalent population of 17,236 cases in 2017.

As per the analysis, a higher percentage of diagnosed prevalence was observed for males, in comparison to females, in all the 7MM countries, except Japan, where females occupy a larger patient pool than males.

Based on the type of RP, it has been assessed that the majority of the patients suffer from non-syndromic RP, with 172,256 cases observed in the 7MM, in 2017, while syndromic and systemic RP cases account for nearly one-fourth of the total RP population.

Scope of the Report
  • The report covers the descriptive overview of Retinitis Pigmentosa (RP), explaining its causes, signs and symptoms, and pathogenesis.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Retinitis Pigmentosa (RP).
  • The report helps to recognize the growth opportunities in the seven major market with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology at the 7MM level by Total Prevalent Population, Gender-specific diagnosed prevalence, Type-specific diagnosed prevalence, Subtype-specific diagnosed prevalence of syndromic and systemic RP, and Subtype-specific diagnosed prevalent cases of non-syndromic RP.
Report Highlights
  • 11-Year Forecast of Retinitis Pigmentosa
  • 7MM Coverage
  • Total Diagnosed prevalent cases of Retinitis Pigmentosa
  • Type-specific prevalent cases of Retinitis Pigmentosa
  • Subtype-specific prevalent cases of Syndromic and Systemic RP
  • Subtype-specific prevalent cases of Non-Syndromic RP
KOL - Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and incidence by the causative pathogen. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
  • What is the disease risk, burden and unmet needs of Retinitis Pigmentosa?
  • What is the historical Retinitis Pigmentosa patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Retinitis Pigmentosa at the 7MM level?
  • What will be the growth opportunities across the globe with respect to the patient population pertaining to Retinitis Pigmentosa?
  • Out of the above-mentioned countries, which country would have the highest Incident population of Retinitis Pigmentosa during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the globe during the forecast period (2020-2030)?
Reasons to Buy

The Retinitis Pigmentosa report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the 7MM Retinitis Pigmentosa.
  • Quantify patient populations in the 7MM Retinitis Pigmentosa market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the causative pathogen that presents the best opportunities for Retinitis Pigmentosa therapeutics in each of the markets covered.
  • The Retinitis Pigmentosa epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Retinitis Pigmentosa epidemiology model is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030
Note: Product cover images may vary from those shown
1. Key Insights

2. Executive Summary of Retinitis Pigmentosa (RP)

3. Retinitis Pigmentosa: Disease Background and Overview
3.1. Introduction
3.2. History
3.3. Facts about Retina
3.4. Signs and Symptoms
3.5. Causes of Retinitis Pigmentosa
3.6. Clinical Features
3.7. Classification of Retinitis Pigmentosa
3.7.1. Classification as per Japanese guidelines
3.8. Pathophysiology
3.9. Etiology
3.10. Genetics of Retinitis Pigmentosa
3.10.1. Types of non-syndromic RP inheritance
3.11. Diagnosis
3.11.1. Recommended Diagnostic Tests
3.11.2. Differential diagnosis of RP

4. Case Reports
4.1. A Case of Unilateral Retinitis Pigmentosa Associated with Full Thickness Macular Hole
4.2. Eleven-Year Follow-Up of a Japanese Retinitis Pigmentosa Patient with an HK1 Gene Mutation
4.3. Unilateral Retinitis Pigmentosa: Visual field changes in a 31-year-old female

5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Epidemiology Methodology
5.3. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the 7MM
5.4. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM
5.5. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM
5.6. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic Retinitis Pigmentosa in the 7MM
5.7. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic Retinitis Pigmentosa in the 7MM

6. United States Epidemiology
6.1. Assumptions and Rationale
6.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the United States
6.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United States
6.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United States
6.5. Sub-Type Specific Diagnosed Prevalence of Syndromic and Systemic RP in the United States
6.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the United States

7. EU5 Epidemiology
7.1. Germany Epidemiology
7.1.1. Assumptions and Rationale
7.1.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Germany
7.1.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany
7.1.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany
7.1.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Germany
7.1.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Germany
7.2. France Epidemiology
7.2.1. Assumptions and rationale
7.2.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in France
7.2.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France
7.2.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France
7.2.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in France
7.2.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in France
7.3. Italy Epidemiology
7.3.1. Assumptions and Rationale
7.3.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Italy
7.3.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy
7.3.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy
7.3.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Italy
7.3.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Italy
7.4. Spain Epidemiology
7.4.1. Assumptions and Rationale
7.4.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Spain
7.4.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain
7.4.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain
7.4.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Spain
7.4.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Spain
7.5. United Kingdom Epidemiology
7.5.1. Assumptions and Rationale
7.5.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the United Kingdom
7.5.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United Kingdom
7.5.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United Kingdom
7.5.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the United Kingdom
7.5.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the United Kingdom

8. Japan Epidemiology
8.1. Assumptions and Rationale
8.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Japan
8.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan
8.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan
8.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Japan
8.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Japan

9. SWOT Analysis

10. Appendix
10.1. Report Methodology

11. Capabilities

12. Disclaimer

13. About the Publisher
Note: Product cover images may vary from those shown
Adroll
adroll